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Effect of Host Sex and Sex Hormones on Muscle-Derived
Stem Cell-Mediated Bone Formation and Defect Healing
Laura B. Meszaros, Ph.D.,1,2 Arvydas Usas, M.D., Ph.D.,1 Gregory M. Cooper, Ph.D.,3
and Johnny Huard, Ph.D.1,2,4
Muscle-derived stem cells (MDSCs) are known to exhibit sexual dimorphism, by donor sex, of osteogenic,
chondrogenic, and myogenic differentiation potential in vitro. Moreover, host sex differences in the myogenic
capacity of MDSCs in vivo are also observed. This study investigated the role of host sex and host sex hormones
in MDSC-mediated bone formation and healing. Using unaltered male, castrated male, unaltered female, and
ovariectomized female mice, both MDSC-mediated ectopic bone formation and cranial defect healing were
examined. Male hosts, whether unaltered or castrated, form significantly larger volumes of MDSC-mediated
ectopic bone than female hosts (either unaltered or ovariectomized), and no differences in ectopic bone volume
were found between hosts of the same sex. In a cranial defect healing model, similar results were found—
unaltered and castrated male hosts display larger volumes of bone formed when compared with unaltered and
ovariectomized female hosts. However, in this healing model, some volume differences were found between
hosts of the same sex. In both models, these differences were attributed to varying rates of endochondral bone
formation in male and female hosts.
Introduction
Muscle-derived stem cells (MDSCs) have been isolatedfrom mouse skeletal muscle using a modified preplate
technique.1–4 MDSCs have been shown to be multipotent,
differentiating into musculoskeletal tissues such as bone,
cartilage, and skeletal muscle, in addition to endothelial,
neural, and hematopoietic tissues.3–9 MDSCs can undergo
osteogenic differentiation with BMP4 treatment in vitro; ret-
rovirally transduced cells can produce high amounts of
BMP4, and these BMP4 transduced cells can then produce
ectopic bone in skeletal muscle, as well as improve bone
healing in critical-sized cranial defects.8–10
MDSCs are known to exhibit sex differences in muscle
regeneration, as well as chondrogenic and osteogenic dif-
ferentiation both in vivo and in vitro.11–13 MDSCs isolated
from female mice have a higher regeneration efficiency when
transplanted into mdx or mdx/SCID mice, a dystrophin-
deficient animal model of muscular dystrophy. In mdx mice,
a significant effect of host sex was also seen, with female
hosts exhibiting higher regeneration.12 Male MDSCs show
superior chondrogenic differentiation in a micromass culture
system in vitro and are also better at repairing a created
osteochondral defects.13 With regards to in vitro osteogenic
differentiation after stimulation with BMP4, MDSCs isolated
from males proved to be superior. Male MDSCs show more
differentiation, as measured through markers of osteogenic
differentiation, including staining for alkaline phosphatase
(ALP), ALP activity, ALP and Runx2 gene expression, and
in vivo implantation of MDSCs of both sexes showed that
male MDSCs produce denser and more consistent volumes
of ectopic bone, while female MDSCs produce variable
volumes of ectopic bone.11
In addition to MDSCs, other progenitor or stem cells also
exhibit sexual dimorphism, by donor sex, of differentiation
potential. Bone marrow stem cells from human females do
not decrease their differentiation potential with the advanced
age of the donor, but differentiation of bone marrow stem
cells from human males does change with donor age.14
Endothelial progenitor cells from male donors are less
migrative and form fewer colonies.15 Bone marrow stem cells
from female donors are more effective at functionally re-
pairing cardiac ischemia than the same cells from male
donors.16 Osteoprogenitors derived from female rat bone
increase proliferation and differentiation in response to
progesterone, while the same cells from male rats do not.17
Adipose stem cells (ASCs) isolated from donors of different
sexes also exhibit divergent differentiation potential. In
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separate studies, male rabbit ASCs are more osteogenic than
those from female donors, while female mouse ASCs are
more adipogenic.18,19 Taking into account sex differences in
cellular progenitor therapies to treat diseases, it will become
increasingly important to consider the sex of a patient when
choosing treatments. Currently, outcomes of transplantation,
whether solid organ or bone marrow, are known to be
affected by the sex of the donor and sex mismatch between
the donor and the host.20 Future stem cell therapies should
include sex considerations, of both host and donor, in order
to maximize positive outcomes.
This study aimed at examining the effect of host sex, as
well as sex hormones, on MDSC-mediated bone formation
and cranial defect healing by utilizing four host groups:
unaltered males, castrated males, unaltered females, and
ovariectomized females. Using microcomputed tomography
(microCT) and histological analyses, bone healing and for-
mation were evaluated to better understand the role of host
sex in MDSC bone therapies.
Materials and Methods
MDSC isolation and transduction
MDSCs were isolated using the following technique
previously described.1,4 Briefly, skeletal muscle from both
lower limbs of a male C57BL/6J mouse was dissected, and
connective and adipose tissues were removed. After fine
mincing, successive enzymatic digestions with collagenase
(Sigma-Aldrich), dispase (Invitrogen) and trypsin (Invitro-
gen) were performed. Finally, a single cell suspension was
achieved by passing a mixture of cell digest and proliferation
medium through 18G, 23G, and 27G needles. Proliferation
medium consisted of the following: high glucose Dulbecco’s
modified Eagle’s medium (Invitrogen), 10% fetal bovine
serum (Invitrogen), 10% horse serum (Invitrogen), 0.5%
chick embryo extract (Accurate Chemical Co.), and 1%
penicillin-streptomycin (Invitrogen). This cell suspension
was then plated onto collagen-coated flasks. After 2 h, non-
adherent cells were transferred from the previous flask to a
new collagen-coated flask. After 24 h, and every 24 h for the
next 5 total days, this procedure of transferring nonadherent
cells to a new collagen-coated flask was repeated. The re-
sulting cells isolated were termed MDSCs.
Based on previous development of retroviral vectors in
our laboratory, a retrovirus called CLB2/4G, encoding for
both BMP4 and green fluorescent protein (GFP), was ap-
plied to MDSCs in a 1:1 ratio with a proliferation medium
with 8 g/mL of polybrene for 24 h.10,21 These retrovirally
transduced cells were then sorted using fluorescence acti-
vated cell sorting (FACS), and only cells expressing GFP
(and, therefore, only cells expressing BMP4) were used in
consequent experiments. These cells were termed MDSC-
B4. Average BMP4 secretion of MDSC-B4 was determined
to be 168 ng/mL by 106 cells in 24 h via human BMP4 ELISA
(R&D Systems).
MDSCs were cultured in proliferation media and main-
tained at a low confluency until sufficient numbers were
reached for experiments. Stocks of transduced MDSCs were
also frozen at a low passage number so that all experiments
could be performed using similar cells. Frozen stocks were
stored in freezing media consisting of proliferation media
and 10% dimethyl sulfoxide.
Surgical procedures
For ectopic bone formation and cranial defect assays, four
host animal groups were used: unaltered male, castrated
male, unaltered female, and ovariectomized female C57BL/
10J mice. All animals were purchased from Jackson Labora-
tories, and castration and ovariectomy were performed be-
fore acquisition at an age of 5 weeks. Surgeries were
performed at an age of 12 weeks. After sacrifice, castration or
ovariectomy was visually confirmed.
For ectopic bone formation assays, 1 day before implan-
tation, 250,000 MDSC-B4 were placed on a 5mm by 5mm by
1mm gelatin sponge and allowed to adsorb onto the surface.
Proliferation medium was then added to cover the sponge,
and the sponges were kept in a normal cell culture condition
overnight until the time of implantation. Following sterile
surgical procedures outlined in the University of Pittsburgh
Institutional Animal Care & Use Committee (IACUC) Pro-
tocol #0807916, each animal was anesthetized, and bilateral
incisions were made in the skin on the back of the hind
limbs. A small pocket was made between the muscles and
the gelatin sponge with MDSC-B4 was inserted. The inci-
sions were then closed with sutures, and the animals were
allowed to resume normal activity. Animals were euthanized
at 21 and 42 days post implantation.
For cranial defect healing assays, sterile surgical pro-
cedures outlined in the University of Pittsburgh IACUC
Protocol #0807916 were followed, and each animal was
anesthetized, and an incision was made along the sagittal
suture. To create the cranial defect, the scalp was dissected,
and 5mm trephine was used to create the circular bone
defect. Just before treatment, 500,000 MDSC-B4 were mixed
with sealer protein solution, and this mixture was applied to
the defect simultaneously with thrombin solution. The sealer
and thrombin solutions are components of the Tisseel fibrin
sealant kit (Baxter Biosurgery), and total volume was*40uL
of fibrin sealant. The incisions were then closed with sutures,
and the animals were allowed to resume normal activity.
Animals were sacrificed at 10 and 28 days after treatment.
MicroCT analysis
Ectopic bone formation was evaluated in all groups with a
microCT scanner (VivaCT40; Scanco Medical) at 7, 14, 21, 28,
35, and 42 days post implantation. Mice were anesthetized
and positioned prone in an animal scanning bed with the
legs fixed in a specially designed holder. For cranial defect
healing, mice were anesthetized and positioned in an animal
scanning bed with the skull in a specially designed holder at
1, 14, and 28 days post treatment. For both assays, scanning
was performed with the following settings: energy of 55 kVp,
intensity of 145mA, nominal resolution of 35mm, and inte-
gration time of 200ms. Two-dimensional image slices were
obtained, and contour lines were drawn to define the volume
of interest (VOI). An appropriate threshold was chosen
for the bone voxels by visually matching thresholded areas
to grayscale images. The threshold was kept constant
throughout the analyses. This led to a three-dimensional
reconstruction of the ectopic bone and provided quantitative
data on bone volume (mm3), presented as mean – standard
deviation. For ectopic bone formation assays, n= 14 unal-
tered male samples, 14 castrated male samples, 14 unaltered
female samples, and 16 ovariectomized female samples. Each
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bilateral implant was considered an independent sample. For
cranial defect healing assays, n = 8 unaltered male samples,
11 castrated male samples, 8 unaltered female samples, and
10 ovariectomized female samples.
Histological analysis
For both assays, after euthanasia, both the ectopic bone
and surrounding muscle tissue or skulls, with the mandibles
and skin removed, were dissected and placed in formalin for
24 h. The samples were then decalcified in 10% ethylene-
diaminetetraacetic acid (Sigma-Aldrich). Dehydration and
then paraffin embedding followed, and samples were cut
into five micron sections and dried.
After deparaffinization and rehydration, sections of ec-
topic bone tissue were stained using standard procedures for
hematoxylin and eosin staining (H&E) to determine general
tissue morphology. Donor cells were distinguished from host
cells by staining for GFP, as all donor cells produced both
GFP and BMP4. Briefly, after blocking in both 3% H2O2 in
methanol and 2% horse serum in phosphate-buffered saline,
biotintylated anti-GFP antibody (Vector Laboratories) was
applied at a 1:1000 dilution. Then, streptavidin/HRP (R&D)
was applied at a 1:50 dilution followed by the DAB Perox-
idase Substrate Kit (Vector Laboratories) as per manufac-
turer’s instructions. Hematoxylin QS (Vector Laboratories)
was used as a counterstain. Resultant staining showed donor
cells expressing GFP (MDSC-B4) as brown and all cells from
the host as purple.
The quantification of histological stains was determined as
follows: for both ectopic bone formation and cranial defect
healing assays, five random 100· H&E images from one
sample were analyzed with ImageJ (NIH) to determine pixel
area of new bone and cartilage tissue. For cranial defect healing,
the pixel area of total visible defect was also calculated. These
pixel areas were then converted to a fraction of new tissue.
Statistical analysis
Sample size of 14–16 ectopic bone implants per host group
and sample size of 8–11 cranial defects per host group were
used for microCT analysis. Bone volume (mm3), bone/
cartilage fraction of ectopic bone (%), and bone/cartilage
fraction of cranial defect area (%) were reported as
mean – standard deviation. Using SPSS statistical software,
two-way repeated measures analysis of variance (ANOVA)
with Tukey’s post hoc analysis was used for ectopic bone
volume, and t-tests were used for bone/cartilage fraction of
ectopic bone. One-way repeated measures ANOVA with
Tukey’s post hoc analysis was used for total and within cra-
nial defect bone volume, and bone/cartilage fraction of the
cranial defect area.
Results
MDSC-mediated ectopic bone formation in four host
groups (unaltered male, castrated male, unaltered female,
and ovariectomized female) was monitored with weekly
microCT scanning, and representative microCT reconstruc-
tions are shown in Figure 1a. In summary, male hosts
(whether unaltered or castrated) form significantly more
bone than female hosts (whether unaltered or ovariecto-
mized) at 21, 28, 35, and 42 days post implantation of MDSC-
B4 infused gelatin sponges, and this is displayed in Figure
1b. However, the volume of bone formed was not different
between unaltered and castrated male hosts or between
unaltered and ovariectomized female hosts. Moreover, via
two-way repeated measures ANOVA, it was determined
that the interaction of volume and time, indicating the rate of
volume accretion over time, was significantly different be-
tween, but not within host sex groups (F = 4.076, p< 0.001).
These volume data are summarized in Table 1.
Since no differences in volume or rate of ectopic bone
formation were seen between hosts of the same sex, that is,
unaltered and castrated male hosts or unaltered and ovari-
ectomized female hosts, only unaltered male and female
host groups were analyzed histologically and displayed in
Figure 2. At 21 and 42 days post implantation of MDSC-B4
infused gelatin sponges, samples from both unaltered male
and female hosts were examined using H&E, as well as GFP
immunostaining to identify donor cells. Through these his-
tological analyses, the process of endochondral ossification
that resulted in ectopic bone formation was evaluated. In ad-
dition, the fates of both donor and host cells were determined.
Representative images of MDSC-mediated ectopic bone
formation in both male and female hosts at 21 and 42 days
post implantation are shown in Figure 2a–h. Male hosts dis-
played bone tissue at both 21 and 42 days, with the latter time
point exclusively showed mature, lamellar bone with fat and
blood cell-filled spaces, resembling marrow cavities (Fig. 2a,
e). In contrast, female hosts at 21 days display large clusters of
chondrocytes with no apparent bone tissue (Fig. 2c). By 42
days, a shell of bone tissue is surrounding the chondrocytes
clusters, but it appears to be less mature bone than is observed
in male hosts, and no marrow-like spaces are seen (Fig. 2g),
indicating that male hosts undergo endochondral ossification
faster than female hosts.
To determine the contribution of donor and host cells to
ectopic bone formation, peroxidase-based immunostaining
for GFP was performed. Donor cells (MDSC-B4) that were
transduced with a retrovirus encoding for both BMP4 and
GFP were stained brown, while host cells were stained
purple (Fig. 2b, f, d, h). As seen in both male and female
hosts, donor cells were found, but host-derived cells pre-
dominate in the ectopic bone tissue. Moreover, in both host
groups, donor cells participated in all aspects of endochon-
dral bone formation. Donor cells are observed as chon-
drocytes, osteoblasts, and osteocytes. However, only cells
from the host fill the marrow-like spaces found in the more
mature bone of male hosts at later time points (Fig. 2f). There
was no marked difference between the number of donor cells
present in male and female hosts at either 21 or 42 days post
implantation. Therefore, it was concluded that although
male and female hosts form differing amounts of bone in
response to MDSC-B4 implantation, and this was due to a
faster rate of endochondral bone formation in male hosts, the
presence of donor cells was not a contributing factor to this
rate difference.
From these histological analyses, the percentages of new
tissue made up of cartilage and bone were determined
(Fig. 2i, j). Female hosts, at both 21 and 42 days post MDSC-
B4 implantation, displayed a larger percentage (0.73 – 0.42
and 0.68 – 0.32) of cartilage tissue in the new tissue formed,
when compared with male hosts at the same time points
(0.24 – 0.25 and 0.0 – 0.0), as seen in Figure 2i. Fraction of
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0.0 – 0.0 indicates that none of the new tissue observed was
cartilage. In contrast, male hosts exhibited a larger percent-
age of bone tissue in the new tissue formed after MDSC-B4
implantation, as seen in Figure 2j (male 21 days 0.76 – 0.26,
42 days 1.0 – 0.0 vs. female 21 days 0.27 – 0.42, 42 days
0.32 – 0.32). Again, the fraction of 1.0 – 0.0 indicates that all
new tissue observed was bone.
MDSC-mediated bone healing was examined in a cranial
defect model, and representative microCT reconstructions of
healing in four host groups (unaltered male, castrated male,
unaltered female, and ovariectomized female) are shown in
Figure 3a. Both within defect bone volume and total bone
volume formed were quantified for each host sex group at
both 14 and 28 days post treatment (Fig. 3b, c). Each host
sex group displayed significantly more bone at 28 days
post treatment than at 14 days, and female hosts (both un-
altered female, 4.08 – 0.74mm3 and ovariectomized female,
4.76 – 1.15mm3) showed significantly less within defect bone
than castrated male hosts (5.82 – 0.74mm3) at 28 days
(Fig. 3b). Moreover, at 28 days post treatment, total bone
volume was significantly less in unaltered female hosts
(75.0 – 26.21mm3) when compared with unaltered male
hosts (109.68– 18.36mm3); ovariectomized hosts also
showed significantly less total bone volume (3.22 – 1.55mm3)
than castrated hosts (7.09 – 2.47mm3) at 14 days post treat-
ment with MDSC-B4, as demonstrated in Figure 3c.
Unlike the previously described ectopic bone formation
experiments, host groups of the same sex (unaltered/
castrated male and unaltered/ovariectomized female) did
have significant differences in some microCT measures;
therefore, all four host groups were histologically examined.
H&E staining (Fig. 4a–h) and GFP immunostaining (Fig. 4i–p)
were performed on sections of each host sex group at various
time points post treatment in order to evaluate MDSC-B4
mediated bone formation and healing of the critical size
cranial defect. Representative images are shown for all
groups at 10 and 28 days post treatment (Fig. 4a–d, i–l,
e–h, m–p respectively).
In all host groups at 10 days post treatment, early endo-
chondral bone formation was observed with some cartilage,
and new bone formed at the defect site (Fig. 4a–d). A trend of
more cartilage in both unaltered and ovariectomized female
hosts was also observed (Fig. 4c–d, q). After 28 days of
treatment with MDSC-B4, male hosts, both unaltered and
castrated, demonstrated endochondral bone formation at
more mature stages of ossification when compared with fe-
male hosts, both unaltered and ovariectomized. At this later
time point, male hosts demonstrated almost exclusively new
FIG. 1. Microcomputed tomography (microCT) reconstructions and volume quantification of ectopic bone in unaltered
male, castrated male, unaltered female, and ovariectomized female hosts. (a) microCT reconstructions of ectopic bone in
unaltered male, castrated male, unaltered female, and ovariectomized female hosts at 14, 21, 28, 35, and 42 days post
implantation of muscle-derived stem cell (MDSC)-B4. Scale bar represents 5mm. (b) volume of ectopic bone formed in
unaltered male, castrated male, unaltered female, and ovariectomized female hosts at 14, 21, 28, 35, and 42 days post
implantation of MDSC-B4. *indicates different from unaltered male at same time, #indicates different from castrated male at
same time ( p < 0.05 for both). Color images available online at www.liebertpub.com/tea
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bone formed at the cranial defect site, with little to no car-
tilage present; this bone was arranged into mature trabecular
bone with marrow-like spaces filled with red blood cells (Fig.
4e, f). However, female hosts still displayed cartilage tissue
with some new bone tissue surrounding it (Fig. 4g, h), sug-
gesting an earlier stage of endochondral ossification. All host
groups significantly increased bone tissue fraction of new
tissue formed from 10 to 28 days post treatment with MDSC-
B4, as displayed in Figure 4r, and at 10 days, unaltered males
(0.15 – 0.09) demonstrated a significantly larger bone tissue
fraction than both castrated males (0.04 – 0.05) and unaltered
females (0.002 – 0.003), also observed in Figure 4r.
GFP immunostaining revealed the contribution of both
donor and host cells to the bone formed at the cranial defect
site. Representative images of all host groups at 10 and
28 days after treatment with MDSC-B4 are shown in Figure
4i–p, with donor cells stained brown and host cells stained
purple. At 10 days after treatment, both donor and host cells
are found in the new bone forming at the defect site in un-
altered and castrated male hosts (Fig. 4i, j). In female hosts at
10 days post treatment, both donor and host cells are seen in
the cartilage phase of endochondral bone formation found in
both unaltered and ovariectomized hosts (Fig 4k, l). Donor
cells are also found interspersed among a majority of host
cells in the proliferative stage of endochondral bone forma-
tion in all groups at 10 days post treatment (Fig. 4i–l). At
28 days after treatment, donor cells are found as osteoblasts,
osteocytes, and chondrocytes (Fig 4m–p). Donor cells were
never observed in the marrow-like spaces present in later
stages of mature bone; these cells were always derived from
the host animal, as seen in Figure 4m–p. Most importantly,
as in bone formation, the majority of cells participating in all
stages of healing of the defect were host derived, regardless
of the sex group of the host.
Discussion
Previous studies using MDSCs found significant differ-
ences in osteogenic, chondrogenic, and myogenic differenti-
ation (both in vivo and in vitro) based on donor sex, in
addition to in vivo differences in muscle repair correlated to
host animal sex.11–13 The present study examined the effect
of host sex and sex hormones on MDSC-mediated ectopic
bone formation and healing of a bone defect. Using four host
animal groups (unaltered male, castrated male, unaltered
female, and ovariectomized female) in ectopic intramuscular
bone formation and cranial bone defect healing models,
microCT analyses and histological stains were evaluated.
FIG. 2. Histological analyses of ectopic endochondral bone formation in unaltered male and unaltered female hosts. (a–d) 21
days post implantation of MDSC-B4 (e–h) 42 days post implantation. Both hematoxylin and eosin (H&E) and green fluorescent
protein (GFP) immunostaining are shown. ‘‘new’’ indicates new bone tissue formed, while ‘‘cart’’ indicates cartilage formed
during the endochondral ossification process. (i) cartilage fraction (%) of new tissue, *indicates different from unaltered male at
same time ( p< 0.05) (j) bone fraction (%) of new tissue, *indicates different from unaltered male at same time ( p< 0.05). Arrows
indicate GFP positive (brown) cells. All images 200· . Color images available online at www.liebertpub.com/tea
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Male hosts, whether unaltered males or castrated males,
displayed significantly more bone formed than female hosts,
whether unaltered females or ovariectomized female, in
ectopic bone formation assays. Similar results of more heal-
ing (larger volumes of bone) were found in MDSC-treated
cranial defects in male hosts compared with female hosts.
Accelerated endochondral bone formation and healing in-
duced by MDSC-B4 treatment was observed in both groups
of male hosts, and this was determined to be the reason for
greater bone formation and healing when compared with
female hosts.
No bone volume differences were observed between male
and castrated groups or between female and ovariectomized
groups, suggesting that sex hormones did not affect MDSC-
mediated ectopic bone formation in this study. These results
were in contrast to previous ectopic bone formation studies,
utilizing demineralized bone matrix, which show sex hor-
mone effects on bone formation in multiple species.22–24 With
regard to native bone maintenance and turnover, ovariec-
tomy is also known to decrease bone volume and quality in
both rats and mice (including the C57BL strain of mice used
in this study).25–29 Normal skeletal bone formation, growth,
and maintenance are all known to be influenced by sex
steroid hormones.30–32 However, MDSC-mediated bone for-
mation appeared not to be influenced by ovariectomy or
castration, which could be promising for translation to clin-
ical therapies.
In this study, ectopic bone was created in the skeletal
muscle of hosts of different sexes. It was observed that the
majority of the cells contributing to new bone tissue are host
derived, either originating from the muscle tissue itself or
traveling from some other location via the circulatory sys-
tem. A factor that could play a role is non hormone-related,
sex-related differences in gene expression of the skeletal
muscle environment surrounding and contributing to the
MDSC-mediated ectopic bone formation. Of the 7367 genes
expressed in murine skeletal muscle, 55.4% of these are
sexually dimorphic.33 Interestingly, four of these sexually
dimorphic skeletal muscle genes are also known to be in-
volved in BMP-induced endochondral ossification.34 If the
bone formation environment (the skeletal muscle in this
model) is innately different between male and female hosts,
this could influence MDSC-mediated bone formation.
MDSC-mediated ectopic bone formation was found to be
affected by host sex, but not sex hormones; however, this
model did not indicate how MDSC-mediated bone repair
may correlate to bone formation. Intramuscular ectopic bone
formation assays, while providing a fast and valuable mea-
sure of the efficacy of osteogenic capacity of cells, materials,
and other therapies, do not fully recapitulate bone formation.
Unlike developmental bone formation or long bone fracture
healing, in ectopic bone formation assays, the endochondral
bone formation cascade is brought about by extrinsic osteo-
genic factors (cells, proteins, or biomaterials) that are not
normal developmental or healing signals. While these factors
can, in fact, induce ectopic bone formation, a bone healing
research model provides more information with regard to
the clinical efficacy of osteogenic therapies. In order to de-
termine whether host sex and/or sex hormones affect bone
repair, MDSC-mediated healing of a cranial defect was
evaluated in unaltered male, castrated male, unaltered
female, and ovariectomized female hosts. Increased bone
formation at the callus site of a long bone fracture has been
correlated to fracture healing.35 Since increased MDSC-
mediated ectopic bone formation was seen in male hosts
compared with female hosts, it was theorized that healing of
a bone fracture or defect may also be accelerated in male
FIG. 3. microCT reconstructions and volume quantification
of cranial defect healing in unaltered male, castrated male,
unaltered female, and ovariectomized female hosts (a)
microCT reconstructions of cranial defect healing at 1, 14,
and 28 days post treatment with MDSC-B4 and representative
coronal slices at 28 days. Scale bar represents 1mm. (b) vol-
ume (mm3) of new bone formed within cranial defect space
post treatment with MDSC-B4. *indicates different from same
host group at 14 days, {indicates different from castrated male
hosts at 28 days. (c) volume (mm3) of total new bone formed
post treatment with MDSC-B4. *indicates different from same
host group at 14 days, xindicates different from castrated male
hosts as 14 days, #indicates different from ovariectomized fe-
male hosts at 28 days, $indicates different from unaltered male
hosts at 28 days (all p< 0.05). Color images available online at
www.liebertpub.com/tea
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FIG. 4. Histological analyses of cranial defect healing in unaltered male, castrated male, unaltered female, and ovariecto-
mized female hosts. (a–d) H&E 10 days post treatment with MDSC-B4 (e–h) H&E 28 days post treatment with MDSC-B4 (i–l)
GFP immunostaining 10 days post treatment with MDSC-B4 (m–p) GFP immunostaining 28 days post treatment with
MDSC-B4 (q) cartilage fraction (%) of new tissue, (r) bone fraction (%) of new tissue. *indicates different from same host
group at 10 days, #indicates different from unaltered male hosts at 10 days. Arrows indicate GFP positive (brown) cells. All
images 200 · . Color images available online at www.liebertpub.com/tea
Table 1. Quantification of Ectopic Bone Formation Volume (mm3) in All Groups
Male Cast Female Ovx
14 days 4.20 – 3.46 6.49 – 3.61 2.65 – 2.88 3.09 – 3.33
21 days 15.51– 12.53 20.82– 10.19 6.71 – 5.91 6.18 – 7.42
28 days 38.85– 28.13 38.17– 19.81 13.32– 12.08 13.29– 15.02
35 days 62.20– 40.17 53.20– 22.49 20.71– 19.56 18.85– 20.54
42 days 81.61– 48.64 64.97– 26.87 28.60– 26.78 25.38– 27.51
All values are mean– standard deviation.
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hosts compared with female hosts. In this bone healing
study, as in ectopic bone formation studies, differences were
found between male and female hosts. However, unlike
ectopic bone formation studies, some measures were also
different between hosts of the same sex: male and castrated
male or female and ovariectomized female.
Some clinical evidence exists that sex may be considered a
factor in fracture healing; however, these studies are usually
retrospective studies evaluating nonunion as an outcome
and do not examine the rate of healing. Female sex is asso-
ciated with increased risk of nonunion in femoral, scaphoid,
and mandibular fractures.36–38 No known studies have ex-
amined host sex or sex hormones in the context of a critical-
sized cranial defect model. However, a few studies have
investigated host sex and sex hormones in long bone fracture
healing.39–42 While the study presented here does not dem-
onstrate differences in bone defect healing between sexes, it
does reveal host sex differences in the response to MDSC-B4
when applied as a bone healing therapy which is important
for translational considerations.
Although some inferences can be made for translational
therapies, it is important to note several limitations of the
data presented. Since MDSCs from male donors have pre-
viously been shown to be more osteogenic and in order to
simplify a complex set of in vivo experiments, only male
donor MDSCs were used to induce bone formation or bone
healing. Although not tested in the current study, it is
expected that male and female hosts would have a similar
response to female donor MDSC-induced bone formation
and healing. In a previous study by our group, differences in
host sex effect on muscle healing showed similar trends,
regardless of donor sex.12 Moreover, bone formed in the
cranial defect studies demonstrates overgrowth of new bone
outside the defect margins; this could be due to the sustained
production of BMP4 protein by retrovirally transduced
MDSCs or caused by overflow of the fibrin sealant contain-
ing MDSCs around the edge of the defect. While this bone
formation was not ideal, the purpose of this study was to
examine the effect of host sex and host sex hormones;
therefore, other variables such as cell type and delivery ve-
hicle were kept constant. Future studies will concentrate on
optimization of these variables for bone healing.
These results suggest that MDSCs, when transduced with
a retrovirus encoding for BMP4, induce endochondral bone
formation, in both an ectopic bone formation and a cranial
bone healing model. The sex of the host, but not sex hor-
mones, affects intramuscular ectopic bone formation; male
hosts demonstrate more rapid bone formation and hence,
larger volumes of ectopic bone formed than their female
counterparts. Similar trends were observed in a cranial defect
healing model, with male hosts forming more bone than
female hosts at the defect site. However, some quantitative
volume differences were found between hosts of the same
sex (castrated and unaltered males or ovariectomized and
unaltered females) that were not observed in an ectopic bone
model. These studies, taken together, demonstrate the im-
portance of taking host sex into account when determining
cell-based osteogenic therapies. Future studies will examine
the methods of modulating and controlling bone formation
and healing differences known to be associated with host
sex, in order to provide better bone healing therapies for both
sexes.
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